Rakuten Medical
Rakuten Medical Raises $100M Series F | Photoimmunotherapy Cancer Treatment
Rakuten Medical Closes $100M for Cancer Treatment
Rakuten Medical, developing photoimmunotherapy treatments for cancer, has raised $100 million in Series F funding led by TaiAx.
Key Highlights
- Currently in global Phase 3 trial
- Novel photoimmunotherapy approach
- Late-stage clinical development
Company Overview
Rakuten Medical is developing a precision cancer treatment using photoimmunotherapy that selectively destroys cancer cells while preserving healthy tissue.
Company Info
Investors (2)
Share
Related Reports
Infisical Raises $40M Series B for AI Agent Security Infrastructure
Infisical raised a $40 million Series B at a $600 million valuation, led by Elad Gil, to expand security infrastructure for AI agents.
Vera Health Raises $28.5M Series A for Clinical AI Search
Vera Health raised a $28.5 million Series A led by Threshold Ventures to further develop its clinical evidence infrastructure and expand into additional healthcare markets.
Omnichat Raises US$10M Series A for Agentic Customer Experience Platform
Omnichat raised a US$10 million Series A led by Openspace Capital to scale its agentic AI platform, deepen R&D on Omni AI Agents and expand globally.
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free